Peptides: what physicians need to know
News, regulation and evidence on peptides in The Bahamas: what the law, the regulators and the studies say, with every fact linked to its source.
Market
GLP-1 Black Market in The Bahamas: Ozempic, Mounjaro and NHI Coverage
Demand for semaglutide and tirzepatide is climbing in The Bahamas, a country ranked first in the Americas for obesity. Prices of $250 to $1,500 a month push patients to unregulated sources, while the government says National Health Insurance will cover GLP-1 drugs.
Read article →
Regulation
Prescription Drugs Without a Prescription: The Bahamas Pharmacy Probe
A Tribune undercover investigation bought antibiotics and pain relievers without a prescription at pharmacies in The Bahamas. The Ministry of Health and Wellness called it unlawful. The Chief Pharmacist says the country still has no national drug registration system.
Read article →
Regulation
LARTA: Stem Cell and Longevity Clinics in The Bahamas, Autism Next
The Bahamas' Longevity and Regenerative Therapies Act, 2024 courts medical tourism with a licensing board and ethics committee. New longevity clinics have opened, and a stem cell centre for paediatric autism is planned in Nassau. The evidence for that indication is thin.
Read article →
Evidence
GLP-1 vs Aspirin for Colorectal Cancer: A Bahamian Researcher's Study
Bahamian oncology fellow Dr Colton Jones led a 281,656-patient real-world study linking GLP-1 drugs to lower colorectal cancer risk than aspirin. Here is what it shows, what it cannot show, and why it matters in The Bahamas.
Read article →
Market
NHI Prescription Drug Programme in The Bahamas: 160,000 and Shortages
The Bahamas is moving its chronic disease prescription drug plan from the National Insurance Board to National Health Insurance and promising free medicines to more than 160,000 Bahamians with chronic diseases. Pharmacists worry about payments and shortages, and GLP-1 drugs are next in line.
Read article →